High levels of SETD3, an HMT that acts on H3K36, have been associated with the development of B-cell lymphoma, hepatocellular carcinoma (HCC), triple negative and p53-positive breast tumors, renal cell tumors, early-stage ovarian carcinoma, and colorectal cancer [2]. This evidence concerns the gene SETD3 and hepatocellular carcinoma.